The anti-KIR antibody (IPH2101) had acceptable safety without significant toxicity or autoimmunity in multiple myeloma (MM) and acute myeloid leukemia (AML) patients (24, 25). This evidence concerns the gene KIR3DL1 and acute myeloid leukemia.